Preparation of recombinant protein of human vascular endothelial cell growth inhibition factor rhVEGI-192A
A technology of VEGI-192A, a growth inhibitor, applied in the biological field
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Publication Date
- 2013-08-07
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention relates to the field of biotechnology, in particular to a method for preparing a recombinant protein of human vascular endothelial cell growth inhibitory factor rhVEGI-192. Background technique
[0002] Vascular endothelial cell growth inhibitory factor (VEGI) is a recently discovered angiogenesis inhibitory factor, mainly produced by vascular endothelial cells. In 1997, Tan et al first discovered human VEGI by screening the cDNA library of human umbilical vein endothelial cells, and named it TLI (TNF-like ligand l) at that time. Subsequent biological activity research found that VEGI can significantly inhibit the proliferation of endothelial cells, hence the name. The full-length VEGI gene is 17Kb, consisting of four exons I, II, III, and IV and three introns. Three kinds of mRNA were spliced according to different splicing patterns, encoding VEGI-251, VEGI-192 and VEGI-174 isoforms composed of 251, 192 and 174 amino acid residues, r...
Examples
Embodiment 1
[0039] Example 2: IPTG-induced expression of rhVEGI-192A in Escherichia coli and screening of highly expressed clones.
[0040] 1. IPTG induction: Use the expression vector pET-30a-rhVEGI-192A to transform the competent cell BL21(DE3)pLysS, randomly pick 16 clones and colonize them in 3 mL LB medium, add kanamycin to a final concentration of 50 μg / ml , 37 ° C recovery culture overnight. The next day, measure the density of each tube of bacterial liquid. If the OD600 is between 0.6 and 1, add IPTG to a certain final concentration, and induce culture for 4 hours. The negative control is induced without adding IPTG. The recombinant expression was analyzed by SDS-PAGE. 183 clonal colonies were obtained.
Embodiment 2
[0041] 2. LB medium: 1% peptone, 0.5% yeast extract, 1% sodium chloride, pH7.0; carbenicillin: 50mg / ml; IPTG solution: 100mmol / L;
[0042] 3. Screening high-expression clones of rhVEGI-192A protein: Using high-throughput SDS-PAGE method, 16 single colonies with the highest expression efficiency were screened from 183 clonal colonies. figure 1 It is the SDS-PAGE results of the lysates of 16 colony colonies obtained from the screening of high-expression clones in the IPTG-induced expression system, in which 1 to 16 are high-expression clone colony groups, C is the clone colony group without IPTG induction, and M is protein Molecular weight standard, the host bacterium is BL21(DE3)pLysS.
[0043] While carrying out subsequent expression and purification procedures, the screened clones were preserved at low temperature - 80°C. After SDS-PAGE, gel scanning software was used to analyze that the expression of the target protein accounted for 44% of the total bacterial protein.
[...
Embodiment 3
[0046] According to the above results, we concluded that the optimal conditions for the expression of rhVEGI-192A protein in BL21(DE3)pLysS host bacteria were the addition of IPTG: 1mM, and the selected culture time: 16h.
[0047] Example 4: Auto-induced expression of rhVEGI-192A in Escherichia coli and screening of high-expression clones.
[0048] 1. Automatic induction: Use the expression vector pET-30a-rhVEGI-192A to transform the competent cell BL21(DE3)pLysS, randomly pick a certain number of clone colonies into 3mL LB medium, add kanamycin to a final concentration of 50μg / ml , 37 ° C recovery culture overnight. The bacterial cell pellet was collected by centrifugation the next day, and the recombinant expression was analyzed by SDS-PAGE.